LIVE NSG552 Module 3 Discussion Latest 2021 February

NSG552 Psychopharmacology

Module 3 Discussion

Anxiety Disorders and Obsessive-Compulsive and Related Disorders

Please refer to the class list tab to see which group you belong in. It is simply a numerical standing based alphabetically. Count your standing from the top down. Class members 1-7 are in Group 1, 8-14 are in Group 2, and 14-20 and beyond are Group 3. This is not a group project. You each post an individual response to the initial topic.

Group 1: Please describe GABA, its role in anxiety and benzodiazepines. What words of caution are prudent when discussing benzodiazepines?

Group 2: Please discuss the role of serotonin in anxiety. Also, why are SSRIs first line treatment in anxiety?

Group 3: Pharmacological treatment strategies for anxiety disorders and OCD seem very similar but there are certain caveats, like differences in evidence or specific FDA indications, for example, that can help to guide your treatment decisions. Discuss the differences in pharmacological treatment you have noted for these four disorders. Citing references like up to date treatment guidelines and primary literature may help your research.

Post your initial response by Wednesday at midnight. Respond to at least one student with a different assigned DB question by Sunday at midnight. Both responses must be a minimum of 150 words, scholarly written, APA formatted, and referenced. A minimum of 2 references are required (other than your text). Refer to the Grading Rubric for Online Discussion in the Course Resource section.